Joe Tippens Protocol, a potential cancer treatment discovered by Joe Tippens.
Among cancer patients and caregivers, the name Joe Tippens is likely familiar. Diagnosed with lung cancer in 2017, Tippens was given only a few months to live. He took the dog dewormer fenbendazole with CBD oil, curcumin, and vitamin E, which was inspired by a scientist's account using the canine cancer drug. Remarkably, his "Joe Tippens Protocol" proved successful, and he remains cancer-free. His story sparked interest in exploring fenbendazole for human cancers.
The initial Joe Tippens Protocol entails taking fenbendazole for three consecutive days, followed by four days off, then repeating the cycle. Unlike many medications, tolerance does not seem to develop with extended fenbendazole use, allowing for indefinite administration if needed. The protocol also advises combining fenbendazole with other things that are believed to enhance efficacy, namely milk thistle, curcumin, and CBD oil.
Link to Joes Blog, it tells the whole story—Worth the read
https://mycancerstory.rocks/the-blog/
For active malignancies, www.fenbendazole.com suggests 444mg of fenbendazole capsules daily, with one day per week off. Tolerance is unlikely, but periodic rest periods may be beneficial. To enhance effects, adding 25mg CBD oil before bed is recommended. Strengthening the regimen with 600mg of curcumin and 250mg of milk thistle (take both twice daily with food) is also advised. Absorption improves when fenbendazole is ingested during or after meals.
Complementary Cancer Treatment:
222mg fenbendazole capsule daily after a fatty meal
600mg curcumin capsule twice daily with breakfast and lunch
25mg CBD oil, 1-2 drops under the tongue before bed
Cancer Relapse Prevention:
222mg fenbendazole capsule once daily after a fatty meal, taken 3 days a week
600mg curcumin capsule twice daily with breakfast and lunch
Milk thistle
25mg CBD oil, 1-2 drops under the tongue before bed
Monitor liver and kidney function tests
Fenbendazole Therapy Tips:
May take 1-4 months to demonstrate anti-cancer effects
Typically compatible with chemotherapy, radiation, surgery
Continue regimen even if cancer improves; tumors recur easily without ongoing treatment, especially aggressive ones
Monitor relevant tumor markers/scans to assess regression
Take with food to improve absorption
Side effects very unlikely; diarrhea possible with extremely high doses
Pause treatment if liver enzymes rise and resume after a 2 week break
May boost tumor radiosensitivity, improving radiation efficacy
Fenbendazole eliminates parasites by inhibiting the production of microtubules, which are structural components of cells that enable intracellular transport. This microtubule disruption also applies to cancer cells, which rely on these structures to sustain their rapid, uncontrolled division. Essentially, fenbendazole stops mitosis by the same mechanism that kills parasites.
Fenbendazole attacks malignancies through several key pathways:
1. Triggering apoptosis (programmed cell death). It does this by arresting the cell cycle via microtubule disruption.
2. Restricting cancer cell glucose uptake. High glucose consumption fuels uncontrolled tumor growth, as seen in PET scans demonstrating the Warburg effect of aerobic glycolysis. Fenbendazole appears to limit this key energy source by reducing glucose transporters and the hexokinase 2 enzyme. This starves cells of division-enabling sugars.
3. Reactivating the tumor suppressor p53 gene. Fenbendazole restores p53 function, which is a strong tumor suppressor. Humans don’t have much of this gene, but fenbendazole helps activate it.
Additionally, malignant cells seem unable to develop resistance to fenbendazole with prolonged use, unlike traditional chemotherapy drugs. This enables long-term administration without loss of efficacy.
A major way cancer cells develop chemoresistance is through P-glycoproteins— special pumps expelling anti-cancer drugs from the cell before they can exert effects. However, research shows malignant cells do not identify fenbendazole as a compound to eject via these pumps. So unlike other agents, fenbendazole remains inside cancer cells. By avoiding efflux by P-glycoproteins, fenbendazole can retain its potency long-term.
The fenbendazole controversy was an incident in which inaccurate claims about the efficacy of fenbendazole, an anthelmintic primarily used to treat various parasitic infections in dogs, in curing terminal lung cancer gained widespread attention among patients.[1] This situation originated with the assertions made by an American cancer patient named Joe Tippens but garnered significant attention, particularly in South Korea. It resulted in nationwide confusion and a surge in the demand for fenbendazole at pharmacies throughout South Korea.
However, it's important to note that Joe Tippens had participated in a clinical trial involving Keytruda, an immunotherapy drug, at the MD Anderson Cancer Center. His reported improvement was likely attributable to the effects of this immunotherapy rather than fenbendazole itself. Initially, South Korean health authorities and experts had issued warnings about potential side effects through press releases on September 23, 2019, but patients chose to disregard these warnings.
Instead, public interest was drawn to a well-known Korean comedian who publicly expressed his intention to use fenbendazole through social media on September 24, 2019, while battling lung cancer. However, by September 2020, this celebrity stated that he would no longer use or endorse fenbendazole, and tragically, he passed away in December 2021.
Indeed, some in-vitro studies have found that fenbendazole has the potential to slow cancer cell growth.[2] However, these are in-vitro studies, meaning they were completed in a petri-dish (glass container), rather than in an animal or human. Unfortunately, results from in-vitro studies are very rarely replicated when carried out in animals or humans. As for research in humans - there is currently no data available on its safety and effectiveness in those with cancer. As for animal-based research - the only study on fenbendazole and cancer was a 2012 study which found that fenbendazole did not affect tumor growth, invasion, or metastasis.[3] Even if there were some positive animal studies as well - this would not be considered enough evidence to support its use in humans as promising research from animal studies is often not replicated in humans.
There are only two small clinical studies that have been completed in humans to treat parasites, listed on the world’s largest medical database - PUBMED.[4] However, these studies were in the context of treating parasites, not cancer. Furthermore, both studies are very small and are from 1970-1980. Outside of these, the safety and effectiveness of the drug has not been adequately tested, and has never been tested on people with cancer.
The Food and Drug Administration (FDA) and European Medicines Agency (EMA) both prohibit fenbendazole for human use. The dose used in animals is greater than 100 fold of the amount that is considered safe for human intake. This is because research has shown risk of serious side effects, such as hepatitis, bleeding and death.[5],[6].
While laboratory research (in-vitro and animal-based) and anecdotal reports may generate interest in using fenbendazole for cancer, it is essential to rely on evidence-based treatments for cancer. Many popular therapies can appear promising at first, but when studied in larger groups of people often fail to show benefit. There is currently a wealth of information on natural therapies already available, with over 50,000 research studies completed in humans with cancer as of 2023. Some of these options have over 100+ studies demonstrating their benefit and safety. At our clinic, we always start with the natural options with the greatest potential for benefit based on the available data.
Patients should always consult with their oncologists or healthcare providers to explore the most appropriate and effective treatment options based on their specific cancer type, stage, and individual health conditions. Research continues to investigate fenbendazole’s potential role in cancer therapy, but until more conclusive evidence emerges, it should not be used as a treatment for cancer.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0275620
Experience with and perceptions of non-prescription anthelmintics for cancer treatments among cancer patients in South Korea: A cross-sectional survey
About half of the cancer patients had taken non-prescription anthelmintics during their chemotherapy, and 96.5% of them did not inform the clinicians. These participants had a positive perception (79.1%) toward the effectiveness of anthelmintics, as they felt it improved their physical condition.
https://ar.iiarjournals.org/content/33/2/355.short
Fenbendazole as a Potential Anticancer Drug
Conclusion: These studies provided no evidence that fenbendazole would have value in cancer therapy, but suggested that this general class of compounds merits further investigation.
https://www.ingentaconnect.com/content/aalas/jaalas/2008/00000047/00000006/art00006
Unexpected Antitumorigenic Effect of Fenbendazole when Combined with Supplementary Vitamins